NCT02861300View on ClinicalTrials.gov

CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 12, 2016

Primary Completion Date

January 10, 2023

Study Completion Date

January 10, 2023

Conditions
Colorectal CancerColon CancerRectal CancerSolid Tumor
Interventions
DRUG

CB-839

Patients will receive CB-839 orally twice daily during each cycle. Each cycle will be 21 days long. Disease assessment will occur after cycle 3.

DRUG

Capecitabine

capecitabine will be given orally twice daily for 14-21 days of cycles. Each cycle will be 21 days long. Disease assessment will occur after cycle 3.

Trial Locations (2)

44106

University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland

44195

Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

David Bajor, MD

OTHER

NCT02861300 - CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer | Biotech Hunter | Biotech Hunter